Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Expression Tech, Eden Biodesign Form Co-marketing Pact

NEW YORK (GenomeWeb News) — Oxford Expression Technologies and Eden Biodesign have struck a co-marketing agreement to serve pharmaceutical researchers involved in protein expression.

Under the agreement, OET will offer access to Eden Biodesign's process development, clinical trial current good manufacturing practice services. Eden Biodesign's customers, in turn, will be able to use OET's range of baculovirus capabilities for their individual protein expression requirements. In particular, Eden's customers will have access to OET's experience in troubleshooting baculovirus expression and the use of its flashback technology for increasing protein yield in difficult to express proteins.

OET was founded in 2007 by a collaboration between Oxford Brookes University and the Natural Environment Research Council to provide custom proteins for research purposes.

Eden Biodesign is focused on guiding clients through process development, manufacturing, regulatory and technology transfer challenges.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.